Opus Genetics (IRD) Receivables - Net (2012 - 2026)

Opus Genetics (IRD) has 10 years of Receivables - Net data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Receivables - Net fell 43.8% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 43.8% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 44.01% from the prior year.
• Receivables - Net for Q1 2026 stood at $1.7 million, down from $2.0 million in the prior quarter.
• Over the last five years, Receivables - Net for IRD reached as high as $10.1 million in Q3 2023 and fell as low as $135000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $2.7 million across 5 years, with a median of $2.0 million in 2024.
• On a YoY basis, Receivables - Net climbed as much as 905.93% in 2024 and fell as far as 81.67% in 2024.
• Year by year, Receivables - Net stood at $1.3 million in 2022, then decreased by 28.66% to $926000.0 in 2023, then soared by 284.77% to $3.6 million in 2024, then sank by 44.01% to $2.0 million in 2025, then dropped by 13.23% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $2.9 million in Q3 2025.